Lauren Royce
Surgical · Clifton, NJNPI 1063861144
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Gilead at 53.0% of the total. Among surgical clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $37.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Ipsen Biopharmaceuticals, Inc$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Madrigal Pharmaceuticals$631
- AbbVie$322
- Intercept Pharmaceuticals, Inc.$168
- plus $296 from 8 others
What the payments were for
- Consulting fees$4,08037%
- Speaking & faculty fees$1,60014%
- Travel & lodging$1,18311%
- Food & beverage$4,22938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 55 | $5,882 |
| Ipsen Biopharmaceuticals, Inc | 19 | $2,399 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 140 | $1,394 |
| Madrigal Pharmaceuticals | 29 | $631 |
| AbbVie | 23 | $322 |
| Intercept Pharmaceuticals, Inc. | 11 | $168 |
| Orphalan Inc | 6 | $102 |
| Argenx US, Inc. | 5 | $75 |
| Dynavax Technologies Corporation | 2 | $30 |
| SK Life Science, Inc. | 1 | $26 |
| AstraZeneca | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,092 in reported general payments places this provider in the 95th percentile of 462 surgical providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 83 | $280,545 |
| Ursodiol | 177 | $21,489 |
| Lactulose | 38 | $1,306 |
| Azathioprine | 29 | $896 |
| Mycophenolate Mofetil | 14 | $891 |
| Carvedilol | 21 | $227 |
| Spironolactone | 44 | $182 |
| Furosemide | 35 | $93 |
| Ciprofloxacin Hcl | 15 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,394 | $280,54583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 462 surgical providers in New Jersey.
Other surgical in Clifton
- Matthew PetridesNeptune$183K
- Andrea ConwayCherry Hill$105K
- Dean BaroneUnion$69K
- Jessica HendersonEatontown$53K
- Richard BengelCamden$44K
- Dylan RyanCamden$26K
- Rachel WintMount Laurel$10K
- Richard HulseNeptune$10K
- Mimi OliffWest Orange$10K
- Gabriella UrsickFlorham Park$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.